3 completed, 2 recruiting, 2 terminated. 6 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 2, Recruiting 2, Terminated 2 |
| Phase 1 | 4 | Completed 2, Recruiting 1, Terminated 1 |
Follow Androgen Receptor Antagonists: new trials by email Literature Review of Androgen Receptor Antagonists trials Research Report on Androgen Receptor Antagonists
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing Cohort 1 (HER2-positive, RC48-ADC), Cohort 2 (NTRK-fusion or NTRK-mutant), Cohort 3 (AR-positive, leuprolide + bicalutamide + abiraterone) - Salivary Gland Carcinoma, Precision Therapy | Phase 2 | Recruiting | Peking Union Medical College | 39 | 2023-08-15 | 2026-04-02 |
| Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer 225Ac-J591, Pembrolizumab, Androgen receptor inhibitor - Prostate Cancer | Phase 1 / Phase 2 | Recruiting | Weill Medical College of Cornell University | 52 | 2021-08-12 | 2026-04-21 |
| Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC) Acapatamab, Enzalutamide, Abiraterone - Metastatic Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Terminated | Amgen | 55 | 2021-01-15 | 2026-08-26 |
| The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC GT0918 - Metastatic Castrate Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Phase 2 | Completed | Suzhou Kintor Pharmaceutical Inc, | 61 | 2019-05-30 | 2024-02-12 |
| Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients TRC253 - Metastatic Castrate-resistant Prostate Cancer, Adenocarcinoma, Prostate | Phase 1 / Phase 2 | Completed | Tracon Pharmaceuticals Inc. | 72 | 2017-05-23 | 2021-04-23 |
| Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer GT0918 - Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Phase 1 | Completed | Suzhou Kintor Pharmaceutical Inc, | 40 | 2016-02-10 | 2020-03-17 |
| Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer Velcade, LH-RH Agonist, Androgen Receptor Antagonists - Prostate Cancer | Phase 2 | Terminated | Medical University of South Carolina | 23 | 2004-10-01 | 2018-11-05 |
Prostatic Neoplasms (2) · Adenocarcinoma (1) · Bites and Stings (1) · Salivary Gland Neoplasms (1)
Suzhou Kintor Pharmaceutical Inc, (2) · Amgen (1) · Medical University of South Carolina (1) · Peking Union Medical College (1) · Tracon Pharmaceuticals Inc. (1) · Weill Medical College of Cornell University (1)
United States (6) · Australia (1) · China (1) · Denmark (1) · Spain (1) · Sweden (1) · United Kingdom (1)
Andrew S. Kraft, MD (1) · Gustavo Leone (1) · James Freddo, MD (1) · Jie Zhang (1) · Phoebe Zhang, PhD (1) · Scott Tagawa, MD, MS (1)